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Rational design, supramolecular synthesis and solid state 
characterization of two bicomponent solid forms of Mebendazole  
Eduardo L. Gutiérrez1, Agustín A. Godoy2, Griselda E. Narda2 and Javier Ellena3* 
Two novel bicomponent solid forms of mebendazole (MBZ), were developed as a mean to modulate its psychochemical 
and pharmaceutical properties. Supramolecular synthesis of MBZ A or C with perchloric or methylsulfuric acids, yields two 
salts of 1:1 stoichiometry which were analyzed through single crystal X-ray diffraction. MBZ perchlorate crystallizes in the 
P21/n space group, while MBZ methylsulfate crystallizes in the P–1 space group. The API and its counter ions are 
interconnected in both crystal packings by a R2
2(8) supramolecular motif. 3-dimentional crystal structure is also stabilized 
by others strong intermolecular hydrogen bonds as well as non-classical interactions. FT-IR spectra are consistent with the 
inclusion of the anions in the crystal structure. MBZ perchlorate is stable up to 210 °C, when it undergoes the endothermic 
loss of the ester moiety. MBZ methylsulfate is stable up to 160 °C when occurs the endothermic elimination of the 
methylcarbamate moiety. The solubility behavior of MBZ perchlorate, studied by UV-visible spectroscopy, suggests an 
improvement by a factor of seven respects to MBZ A, in the apparent solubility of MBZ in 0.1 mol L–1 HCl. Further 
experiments are required to evaluate both the stability of the solids and the maximum solubility of the API. 
Introduction 
Mebendazole (MBZ, methyl N-(5-benzoylbenzimidazol-2-yl) 
carbamate, Scheme 1) is a broad-spectrum benzimidazole-
derivate anthelmintic and postulated as a possible antitumor 
drug.
1
 It is a Class II drug of the Biopharmaceutical 
Classification System
2
 due to its poor solubility either in water 
or 0.1 mol L
–1
 HCl (aq) but high permeability
3
 and it is included 
in the World Health Organization (WHO) Model List of 
Essential Drugs
4
. This active pharmaceutical ingredient (API) 
presents three polymorphs named as A, B and C that exhibit 
marked differences in their physicochemical properties and 
bioavailability.
5
 MBZ A is the least water soluble form being 
MBZ B the most soluble one, while MBZ C presents an 
intermediate solubility value (9.84 ± 0.05, 71.3 ± 0.5 and 35.4 ± 
0.5 mg L
–1
 respectively in pure water). This last one solid form 
is the therapeutically preferred one to treat several parasite 
infections (ascariasis, uncinariasis, oxyuriasis, and 
trichuriasis)
6–8
. Such is the importance of the polymorph 
choice that the International Pharmacopoeia 5
th
 Edition 
restricts the suitable polymorphic form to MBZ C in chewing 
tablets, emphasizing that the overall manufacturing process 
should be designed and controlled to minimize its conversion 

























Scheme 1. Above: the 1H-tautomer of MBZ found in polymorph C.  
Below: The 3H-tautomer found in MBZ A. 
 
MBZ presents enamine-imino tautomerism in solution.
10
 As 
stated by Agatonovic-Kustrin et al.
8
, tautomerism is 
responsible for MBZ polymorphism. The 1H-tautomer shown 
in Scheme 1 (above) is the only one present in MBZ polymorph 
C, while MBZ polymorph A is formed by the crystallization of 
the 3H-tautomer shown in Scheme 1 (below). The crystal 
structure of polymorphs A and C have been previously 
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reported
11,12
, while the structure of polymorph B remains 
undetermined. These three polymorphs show differences in 
their physicochemical and mechanical properties, which are 
related to numerous other pharmaceutical interesting 
properties (drug dissolution, absorption and bioavailability, but 
also manufacturing reproducibility, stability in storage and 
transport, etc.). De Villiers et al. have studied the thermal 
stability of MBZ polymorphs.
13
 They characterized the first-
order phase transition from polymorph C to A at approx. 200 
°C and found evidence of a similar transformation from MBZ B 
into MBZ A. It have been recently reported that the MBZ most 
stable form A does not melt but rather decomposes above its 
thermal stability of approx. 200 °C.
14,15
  
Regarding the relationship between the physicochemical 
properties and pharmaceutical performance, on one hand due 
to its high stability and therefore extremely low water 
solubility, therapeutic assays suggest that MBZ A has similar 
efficacy to placebos in controlling worm infections. On the 
other hand, the most soluble and least stable polymorph B has 
shown to be more toxic during both anthelmintic and 
anticancer tests.
16
 MBZ C falls right into the therapeutic 
window, since its dissolution profile and its solubility ensure 
acceptable efficacy, meanwhile concentration values that can 
cause toxicity are not reached. However, polymorph 
interconversion has been demonstrated to occur in tablets 
prepared with form C, which suffer a transformation to 
products containing form A under the effects of moisture and 
heat. Due to the same phenomenon, suspensions of 
polymorph C may also contain part of their active principle 
converted to polymorph A.
17
 This polymorph interconversion 
in solid drug formulations is a big problem for the 
pharmaceutical industry. 
In this work, we developed two novel bicomponent solid 
forms of MBZ aiming to increase the knowledge about its 
intermolecular interactions as a mean to explore the possible 
ways to modulate properties such as solubility and thermal 
stability and to avoid polymorph interconversion. The design 
and synthesis of multicomponent systems using crystal-
engineering techniques is a strategy widely used to improve 
the performance and processability of Active Pharmaceutical 
Ingredients (APIs). This approach has been also used to 
modulate the pharmacokinetic properties of the API solid form 
since it does not modify the intrinsic chemical structure of the 
drug but only its supramolecular environment.
18,19
  
Here we use methylsulfuric (HSO4CH3) and perchloric 
(HClO4) acids as coformers. HSO4CH3 is used as counterion in 





 In contrast, there is not much literature about 
multicomponent drug crystals incorporating perchloric acid 
and.
21
 Since sulfur and chlorine present similar size, HClO4 was 
chosen as a HSO4CH3 analogue in an attempt to evaluate the 
effect in the crystal packing of the presence/absence of methyl 
group in the coformer. Both systems were designed based on 
the statistical probability of formation of a supramolecular 
heterosynthon of the   
 ( ) type
22
 between the MBZ molecule 
and the appropriate coformers instead of the highly stable 
MBZ⋯MBZ homosynthon (Tables S1 & S2, Electronic 
Supplementary Information –ESI–). As shown in Scheme 1 
(above), MBZ 1H-tautomer exhibits one polarized N1–H bond 
that could act as hydrogen-bond (H-bond) donor, and one 
basic site on N2 that could act as H-bond acceptor; this 
particular structure may allow the assembly of one MBZ 
molecule with a suitable coformer by two complementary 
intermolecular hydrogen bonds. Another similar R2
2
(8) synthon 
could be designed for the 3H-tautomer (Scheme 1, below) 
involving N3 as H-bond acceptor and N1–H as H-bond donor. 
In the Tables S3 & S4 we present the  R2
2
(8) synthons found 
among the cocrystals and salts reported in the literature
23–28
, 
including one nitrate salt previously reported by us
29
. 
Concerning these specific chosen coformers, we also had to be 
aware of possible proton transfer, prior to crystallization, and 
therefore the salification of the API. Drug salts usually tend to 
convert to the raw APIs. Previous reports show that MBZ salts 
undergo a solvent-mediated transformation to pure MBZ 
polymorph C
29,30
. Here we focus mainly on the description of 
the crystal structure of these systems, the study of its thermal 
stability and the corresponding suspension stability of both 
new solid forms. Hirshfeld surface analysis was performed to 
complement the atom-by-atom analysis of intermolecular 
interactions and the relative stability of both compounds. The 
Hirshfeld surface emerged from an attempt to define the 
space occupied by a molecule as whole in a crystal for the 
purpose of partitioning the crystal electron density into 
molecular fragments. Since this surface is defined by the 
molecule and the proximity of its nearest neighbours, it 
encodes information about intermolecular interactions which 





Samples of MBZ (295.29 g mol
–1
) polymorphs A and C were 
kindly provided by Laboratorio de Control de Calidad de 
Medicamentos, UNSL. Purity of these samples was checked 
using PXRD. Absolute methanol (CH3OH, Sintorgan, analytical 
grade) was used, without any further purification, as solvent 
for the suspension and dissolution of the drug. Perchloric acid 
(70% w/w, 1.68 g mL
–1
 (20 °C), 100.46 g mol
–1
) and sulfuric acid 
(H2SO4, 98% w/w, 1.84 g mL
–1
, (20 °C), 98.08 g mol
–1
) were 
obtained from Merck and Tetrahedron, respectively, and used 
without further purification too. Methylsulfuric acid (also 
known as methyl bisulfate due to its monoprotic nature, 
112.10 g mol
–1
) was synthesized by direct esterification of 
H2SO4 with CH3OH
33,34
. The reaction was carried out by slowly 
mixing 1 mL H2SO4 98% w/w with 9 mL of absolute CH3OH in 
an open vessel at room temperature (approx. 22-25 °C) 
(Caution: very exothermic reaction). Esterification was verified 
using UV-Vis spectroscopy. 
 
Supramolecular synthesis 
A sample of MBZ polymorphs A or C of approx. 25 mg (0.10 
mmol) was suspended in 10 mL of absolute CH3OH at room 
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temperature with constant magnetic stirring (500 rpm), 50 μL 
of acid solution (HClO4: 0.60 mmol and HSO4CH3 0.10 mmol) 
were added to achieve complete dissolution of the solid. After 
10 min stirring, the solution was filtered. Finally, the solution 
was brought to 5 °C to achieve slow evaporation of the 
solvent. After approx. seven days, the formation of small, 
prismatic crystals was observed. These crystals were separated 
by filtration and washed several times with n-hexane. Powder 
X-ray diffraction and FT-IR spectroscopy were used to check 
the purity and identity of the solids, which were then kept at 
room temperature for further characterizations.  
As mentioned before, it is important to be aware about the 
possible salification of the API. The empirical “pKa Rule” states 
that salt should be expected when the difference in pKa 
between the conjugated acid of the base and the acid is 
greater that approx. 2-3 units. Considering the values of pKa of 




) and those of HClO4 (–10) 
and HSO4CH3 (–2.6), a proton transfer prior to crystallization is 
very likely (ΔpKa,1 = 14.43 and ΔpKa,2 = 7.03) which need to be 
confirmed by SCXRD. 
 
Powder X-ray diffraction 
Powder X-ray diffraction (PXRD) analysis was performed on 
a Rigaku Ultima IV diffractometer (Rigaku Corporation) using 
Cu Kα radiation, in a step mode, between 3-50° in 2θ with a 
scanning rate of 0.6° min
–1
 (2 s per step) and a step of 0.02°. 
The powder diffraction patterns were collected and processed 





Fourier transformed infrared spectrum were recorded on a 
Nicolet Protègè 460 spectrophotometer (Nicolet Instrument 
Corporation) provided with a CsI beamsplitter, in the 4000-400 
cm
–1
 range with 64 scans and spectral resolution of 4 cm
–1
, 
using the KBr pellet technique. Measures were collected and 
processed with the software «Omnic», associated to the 
spectrometer. The spectra at controlled increasing 
temperatures were obtained by placing the pellet in a variable-
temperature homemade cell in the 25 °C - 250 °C range within 
air atmosphere. 
 
Single-crystal X-ray diffraction 
Suitable-sized clear crystals were selected for the single 
crystal X-ray diffraction experiments. The data were collected 
at room temperature (293(2) K) on a Bruker APEX-II 
diffractometer with CCD detector system equipped with a Mo 
source (λ = 0.71073 Å). Data integration, cell determination 
and final parameters were obtained using the software Bruker 
SAINT
36
 included in APEX2
37
 software suite. The structures 
were solved by direct methods through the program SHELXLT
38
 
and the model obtained was refined by full matrix least 
squares on F2 using the program SHELXLT
38
, included in 
Olex2
39
 software. All the hydrogen atoms were placed in 
calculated positions and refined with fixed individual 
displacement parameters [Uiso(H) = 1.2 Ueq or 1.5 Ueq] 
according to the riding model. The crystallographic 
information files (CIFs) were deposited in the Cambridge 
Structural Data Base
40
 under the codes CCDC 1995782 and 
1995783. Copies of the data can be obtained, free of charge, 
via www.ccdc.cam.ac.uk. Geometrical calculation, molecular 
representations, pictures and tables were performed by 










Hirshfeld surface analysis 
Hirshfeld surface analysis was performed using the 
software CrystalExplorer17
44
 using the CIFs as input files. 
Hirshfeld surfaces for MBZH⋅ClO4 and MBZH⋅SO4CH3 were 
mapped with dnorm over the range –0.35 to 1.25. Shape index 
and curvedness surfaces were mapped over the ranges –1.0 to 
1.0 and –4.0 and 0.4 respectively. 2D-fingerprints plots were 
obtained for de y di between 0.4 and 2.6. 
 
Thermal analysis 
Thermogravimetric analysis (TGA) and differential thermal 
analysis (DTA) measures were obtained simultaneously with a 
Shimadzu DTG-60 instrument (Shimadzu Inc.), using platinum 
pan, flowing air at 20 mL min
–1
, and a heating rate of 10 °C 
min
–1
 from room temperature (RT) to 600 °C. TGA and DTA 
curves were collected and processed with «TA60» software, 
associated to the analyser. 
 
UV-visible spectroscopy, solubility and stabilities studies 
UV-visible absorbance measures were carried out in an 
Agilent 8454 UV-vis spectrophotometer (Agilent Technologies), 
collected and processed with «8453 UV Visible Chem station 
Rev.A.10.01» software associated to the instrument. 
Equilibrium solubility of MBZH⋅ClO4 at room temperature 
was evaluated and compared against those of mebendazole 
polymorphs A and C in 0.1 mol L
–1
 hydrochloric acid solution, 
using the shake flask saturation method
45
. Saturated solutions 
of the three solids were prepared by stirring an excess amount 
of the solids into 4 mL of the dissolution medium for a period 
of 48 hs (20 °C and 200 rpm) in a SI-300R shaker (Lab 
Companion). After sedimentation, the solutions were filtered 
through a 0.45 mm filter (Exacta). The identity of the solid 
sediments was checked by PXRD. UV-Vis spectroscopy was 
employed to measure MBZ concentration in the saturated 
solutions, applying a direct calibration method, using the 
absorbance maxima as a parameter proportional to the 
concentration. Saturated solutions were diluted in the 
dissolution medium to ensure working on the 
spectrophotometer linear range of response.  
Results and discussion 
Crystalline habit, identity and purity 
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MBZH⋅ClO4 crystallize as yellowish/brownish small 
prismatic crystals, while MBZH⋅SO4CH3 crystallizes as 
elongated prismatic colorless crystals in the shape of needles 
(Figure S1, ESI).  
Preliminary evidence about the identity of presumably new 
solid products was provided by their vibrational spectra and 
their powder X-ray diffractions patterns. These measures were 
performed prior to the single-crystal X-ray diffraction 
experiments. Ayala et al.
46
 have established that the position 
of the band corresponding to the carbamate carbonyl 
stretching mode could fingerprints the crystalline forms of 




 and 1697 cm
–
1





 in the MBZH⋅ClO4 and MBZH⋅SO4CH3 spectra, 
respectively. Further evidence of the inclusion of the anions in 
the crystal structure was given by the identification of other 
bands. The bands assigned to the ν3 and ν4 modes of the 
perchlorate anion appears at 1115 cm
–1
 and 625 cm
–1
, and the 
bands of the same modes of methylsulfate anion were found 
at 1113 cm
–1
 and 614 cm
–1
. The bands corresponding to 
stretching modes of the methyl group of the anion appears at 
2850 cm
–1
 and 2815 cm
–1
, while the stretching modes of the 
methyl group of the carbamate moiety of MBZ are at 2955 cm
–
1
 and 2917 cm
–1
. IR spectra are shown in Figure S2. 
The same solid MBZH⋅ClO4 form was obtained from both 
MBZ A and MBZ C polymorph, while the solid MBZH⋅SO4CH3 
was obtained just from MBZ C (synthesis from MBZ A was not 
tested). We compared the powder X-ray diffractions patterns 
of both solids with those calculated for MBZ A and MBZ C, and 
the experimental one of MBZ B previously reported
24,47
 (Figure 
1). This comparison ruled out the formation of any of the three 
polymorphs after solvent evaporation as a sub-product, since 
none of their characteristic peaks were observed in the 
experimental patterns of MBZH⋅ClO4 and MBZH⋅SO4CH3. With 


















Figure 1. Experimental Powder X-ray diffractions patters of MBZ 
perchlorate and MBZ methyl sulfate compared with those calculated 
from solved structures. 
 
PXRD pattern and FT-IR spectra analysis showed that both 
compounds, kept at room temperature, were stable in the 
solid state for at least for one year after the synthesis, and no 




Single-crystal X-ray diffraction experiments confirmed the 
formation of two new solids, mebendazole perchlorate 
(MBZH⋅ClO4) and mebendazole methylsulfate (MBZH⋅SO4CH3). 
Both solids are ionic with a 1:1 stoichiometry. 
 
Mebendazole perchlorate salt. This salt crystallizes in the 
monoclinic P21/n (14) space group. Crystal data, data collection 
and structure refinement parameters are shown in Table 1. 
The crystal structure shows the total proton transfer from 
the perchloric acid to the N2 of the imidazole ring of the drug, 
resulting in an ionic solid. An ORTEP type view of the 
asymmetric unit of MBZH⋅ClO4, displaying the atoms labelling 




Figure 2. View of MBZ perchlorate (A) and MBZ methylsulfate (B) 
asymmetric units, showing the atoms labelling and the 50% probability 
ellipsoids for non-hydrogen atoms. The hydrogen atoms are shown as 
sticks of arbitrary radii. (Color code. C: grey; H: white; O: red; N: blue; 
Cl: green; S: yellow.) 
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Table 1. Crystal data, data collection and structure refinement parameters of MBZ perchlorate and MBZ methylsulfate. 
Table 1 
Identification code MBZ perchlorate (MBZH⋅ClO4) MBZ methylsulfate (MBZH⋅SO4CH3) 
Empirical formula C16H14ClN3O7 C17H17N3O7S 
Formula weight 395.75 407.39 
Temperature / K 293(2) 293(2) 
Crystal system monoclinic triclinic 
Space group P21/n (14) P–1 (2) 
a / Å 6.7934(7) 9.1092(11) 
b / Å 9.2159(14) 9.9717(14) 
c / Å 27.264(5) 9.9908(14) 
α / ° 90 92.075(12) 
β / ° 93.007(12) 102.401(11) 
γ / ° 90 90.209(10) 
Volume / Å
3
 1704.5(4) 888.7(2) 
Z/Z’ 4 2 
ρcalc / g/cm
3
 1.542 1.528 
μ / mm
-1
 0.27 0.23 
F(000) 816 424 
Crystal size / mm
3
 0.25 × 0.18 × 0.15 0.16 × 0.05 × 0.02 
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection / ° 5.338 to 68.86 5.469 to 69.066 
Index ranges –10≤h≤9, –21≤k≤14,  –40≤l≤34 –14≤h≤10, –15≤k≤14,  –13≤l≤35 
Reflections collected 10221 7683 
Independent reflections 6430 [Rint = 0.066, Rsigma = 0.144] 64296 [Rint = 0.031, Rsigma = 0.115] 
Data/restraints/parameters 6430/0/246 6296/0/255 
Goodness-of-fit on F
2
 1.03 1.05 
Final R indexes [I2σ(I)] R1 = 0.092, wR2 = 0.204 R1 = 0.065, wR2 = 0.151 
Final R indexes [all data] R1 = 0.244, wR2 = 0.285 R1 = 0.164, wR2 = 0.188 
Largest diff. peak/hole / e Å
–3
 0.54/–0.34 0.29/–0.35 
 
Table 2. Hydrogen-bonding geometry for MBZ perchlorate and MBZ methylsulfate 
Table 2 
MBZ perchlorate 
D–H⋯A D–H / Å  H⋯A / Å D⋯A / Å D–H⋯A angle / ° 
N3–H⋯O2  0.86 2.19 2.698(5) 117 
N2–H⋯O4  0.86 1.94 2.787(5) 167 
N1–H⋯O5  0.86 2.04 2.875(5) 162 
N3–H⋯O7 
a
 0.86 2.14 2.919(5) 151 
C7–H⋯O6 
b
 0.93 2.58 3.388(7) 146 
MBZ methylsulfate 
D–H⋯A D–H / Å  H⋯A / Å D⋯A / Å D–H⋯A angle / ° 
N3–H⋯O2   0.86 2.21 2.710(3) 117 
N2–H⋯O4   0.86 1.89 2.742(3) 170 
N1–H⋯O5   0.86 1.90 2.736(3) 163 
N3–H⋯O7 
c
 0.86 2.04 2.800(3) 147 
C7–H⋯O6 
d
 0.93 2.55 3.314(3) 140 
C17–H⋯O2 
e
 0.93 2.53 3.422(4) 154 
D: donor. A: acceptor 
Equivalent positions: 
a: x, y+1, z                      b: x+1, y+1, z       c: x–1, y, z          
d: –x+1, –y+1, –z+1       e: x+1, y, z 
 
Protonation causes changes in the bond lengths of the 
imidazole ring. In the crystal structure of polymorph C
12
, the 
length of the amine (N3–C3) and imine (N2–C3) bonds are 
significantly different: 1.349(9) Å and 1.30(1) Å, respectively. 
On the other hand, in the MBZH
+
 cation, the bond N2–C3 is 
1.337(6) Å and the bond N3–C3 is 1.321(6) Å, showing a partial 
loss of the double bond character due to the presence of a 
positive charge on N2. This behavior is caused by the 
displacement of the negative charge on the ring as a 
ARTICLE Journal Name 
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consequence of protonation. It is also worth noting that 
protonation shortens the length of the bond N1–C3, due to an 
additional displacement of electron density from N1 towards 
the site of protonation. This bond is 1.37(1) Å in MBZ C, while 
it is 1.341(6) Å in MBZH
+
, suggesting a higher double bond 
character (Figure S4). These observations are consistent with 
the behavior exhibits by protonated MBZ molecule in all 
reported structures. 
In the MBZH⋅ClO4 crystal structure the MBZH
+
 cation shows 
a methylcarbamate group coplanar with the benzimidazole 
ring, forming an intramolecular resonance-assisted H-bond 
(RAHB)
48
 between the carbonylic oxygen O2 (acceptor, A) and 
the imidazolic nitrogen N3 (donor, D; A⋯H: 2.19 Å, Table 2). 
The MBZH
+
 cation also shows a dihedral angle of 51.6(2)° 
between the least squares planes determined by the 
benzimidazolic and benzoyl rings (Figure 3.D). 
The asymmetric unit of the solid consists of one MBZH
+
 
cation and one ClO4
–
 anion. Both ions form a supramolecular 
motif of the R2
2
(8) type stabilized by two intermolecular H-
bonds: N1–H⋯O5 (A⋯H: 2.04 Å) and N2–H⋯O4 (A⋯H: 1.94 Å) 
(Figure 3.B). In Table S3 we collected the H-bond distances of 
all MBZ salts that presents this supramolecular motif (no 
cocrystals were found exhibiting this synthon). This 
arrangement is not coplanar: there is a dihedral angle of 
23.0(3)° between the planes determined by the atoms N3, C3 
and N1, and the atoms O4, Cl and O5 of the perchlorate anion.  
 
 
Figure 3.A. Antiparallel chains along b axis of ionic pairs 
MBZH+/ClO4
– assembled by intermolecular H-bonds.  
B. Supramolecular motif R2
2
(8) formed by one MBZH+ cation and 
one ClO4
– anion. C. Arrangements of MBZH+ in the plane ac stabilized 
by a peculiar benzoyl/imizadole interaction. D. Conformation of MBZH+ 
cation in the crystalline state. (Color code. C: grey; H: white; O: red; N: 
blue; Cl: green.) 
 




 are connected along the b axis 
through H-bond interactions between the atom N3 of one pair 
and the atom O7 of the next pair (A⋯H: 2.14 Å). These chains 





pairs of opposite chains related by an inversion centers (Figure 
3.A). In the ac plane, there is a short contact that contributes 
to crystal packaging, which was not found in others solid forms 
of the drug: the imidazolic N2 connects with the bezoylic O3 of 
an adjacent molecule (3.012(5) Å). This interaction, also 
revealed by Hirshfeld surface analysis (see below), gives rise to 
the arrangement of MBZH
+
 shown in Figure 3.C. Numerous 
other short-contact interactions can be found, which 
contribute to final stabilization of the crystal packing; among 
them, the C3⋯O3 (2.951(6) Å) contact that reinforces the 
N2⋯O3 interaction. The oxygen atoms of the perchlorate 
anions, where lies the negative charge of the compound, are 
involved in various short-range interactions. For instance, the 
atoms O5 and O7 interact with the atoms C2 and C1 of the 
methylester group at the end of a contiguous MBZ molecule in 
the ac plane 
 
Mebendazole methylsulfate salt. Mebendazole methylsulfate 
crystallizes in the triclinic P–1 (2) space group. Crystal data, 
data collection and structure refinement parameters are listed 
in Table 1. An ORTEP type view of the asymmetric unit of 
MBZH⋅SO4CH3, displaying the atoms labelling and the 50% 
probability ellipsoids, is shown in Figure 2.B. 
Protonation on N2 produces here the same effects on the 
bond lengths of the imidazole ring as described in the previous 
section. Imine and amine bonds are very similar: the bond 
between N2–C3 is 1.326(4) Å, and the bond N3–C3 is 1.338(3) 
Å. The displacement of the electron density also shortens the 
length of the bond linking imidazole ring to the carbamate 
moiety (N1–C3: 1.341(3) Å) (Figure S4). In this salt, the MBZH
+
 
cation is found in a molecular conformation similar to the one 
adopted in the MBZH⋅ClO4 crystal structure. The benzimidazole 
ring is coplanar with the carbamate moiety, and the 
resonance-assisted intramolecular H-bond between the 
imidazolic N3 and carbonylic O2 (A⋯H: 2.21 Å, Table 2) is also 
present. The dihedral angle determined by the least-square 
planes through the benzimidazolic and the benzoyl rings is 
54.32(14)°.  
The crystal packing of the MBZH⋅SO4CH3 also shows the 
presence of infinite chains connected by the same 
intermolecular synthon with R2
2
(8) motif, but in this case along 
the crystallographic a axis. These chains are stabilized by two 
intermolecular H-bonds: N1–H⋯O5 (A⋯H: 1.90 Å) and N2–
H⋯O4 (1.89 Å) (Figure 4.C). This arrangement is almost planar: 
there is a dihedral angle of just 7.12(10)° between the least-





 pair is connected to the next ionic 
pair through two intermolecular H-bond: N3–H⋯O7 (2.04 Å) 
and C17–H⋯O2 (2.53 Å). These interactions form antiparallel 
chains in the [100] direction. Ionic pairs of adjacent chains are 
related again by an inversion center, giving rise to the 
formation of dimers.  
In bc plane, antiparallel chains are connected by a short 
contact between O7 and N1 (2.988(3) Å) (Figure 4.A). This 
inter-chains contact connect the chains in a A⋯B C⋯D 
sequence, since all polarized groups are exposed between 
chains “A” and “B”, and “C” and “D”, awith methyl groups from 
methylsulfate anions laying between chains “B” and “C”. Two 
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non-classical H-bonds are found between chains “B” and “C” in 
which one methylsulfate from chain “C” acts both as acceptor 
(O6⋯H–C7, 2.55 Å) and donor (C17–H⋯O3, 2.68 Å) (Figure 
4.B). 
Adjacent chains are connected by two different contacts: 
one non-classical H-bond between O5 and C13 (A⋯H: 2.68 Å), 
and one interaction between the bezoyilic O3 of one MBZH
+
 
and C1 of next cation (3.213(4) Å), forming infinite layers 
parallel to a axis (Figure S5).  
 
 
Figure 4.A. Antiparallel chains along a axis of ionic pairs 
MBZH+/SO4CH3
– assembled by intermolecular H-bonds.  
B. Short-contact interactions C–H⋯O between “B” and “C” chains.  
C. Supramolecular motif   
 ( ) formed by one MBZH+ cation and one 
SO4CH3
– anion. (Color code. C: grey; H: white; O: red; N: blue; S: 
yellow.) 
 
Hirshfeld surface analysis. Hirshfeld surface analysis shows that, 
as expected, the predominant intermolecular interactions are 
the N–H⋯O H-bonds described in the previous sections, with 
the three N atoms of MBZH
+
 acting as donors. These short H-
bonds are associated with two large red spots on the dnorm 
[from -0.35 (blue) to 1.25 Å (red)] mapped on the Hirshfeld 
surface of the cation (Figures 5A & B).  
However, the observation of the dnorm surface of MBZH
+
 
reveals that the N3–H⋯O7 interaction is reinforced by an 
additional non-classical interaction C6–H⋯O4 (A⋯H: 2.68 Å in 
MBZH⋅ClO4 and 2.62 Å in MBZH⋅SO4CH3) (Figures 5C & D). 
Furthermore, there is another non-classical interaction C17–
H⋯O2 (2.53 Å) in MBZH⋅SO4CH3 in which the MBZH
+
 cation 
acts as acceptor through the carbamic O. These longer 
contacts (and therefore weaker) are shown as faint red spots 
visible on the dnorm surface (Figures 5D).  
The intermolecular contact N2⋯O3 (3.012(5) Å) found in 
MBZH⋅ClO4 is reinforced by another short contact interaction 
between O3 and C3 (2.951(6) Å) (Figure S6A). Both 
interactions are associated with a large red spot around O3 on 
the dnorm surface. 2D-fingerprint plot reveals that this red spot 
presents an important contribution from this C⋯O contact 
(Figure S6B). The assembling of MBZH
+
 cations in the ac plane 
is also stabilized by carbonyl···π interactions between the 
benzimidazole moiety of one MBZH
+
 and the carbamate 
moiety of the next molecule, revealed by the pattern of red 
and blue triangles on the shape index surface (Figure S7A). 
Curvedness surface plots show flat patches above one side of 
the benzimidazole ring, and on the opposite side above the 
carbamate moiety, suggesting the same pattern of planar 
stacking of MBZH
+
 molecules (Figure S7B). These interactions 
are absent in MBZH⋅SO4CH3 and the arrangement of infinite 




Figure 5. MBZH+ cations in MBZH⋅ClO4 (A & C) and MBZH⋅SO4CH3 (B & 
D) mapped with dnorm surface. 
 
Thermal stability 
Thermal analysis revealed MBZH⋅ClO4 is stable up to 210 
°C. DTA and DSC curves show a first endothermic event (Temp. 
onset 210 °C, Temp. centered at 239 °C) associated with a 
relative mass loss of 14.77%, as demonstrated by the TGA 
experiment, which is consistent with the mechanism proposed 
by Holanda et al. for MBZ degradation in air to form 2-amino-
5-benzoylbenzimidazole
14
. The loss of the methylester moiety 
in MBZH
+
 cation implies a theoretical mass loss of 14.66%. In 
order to obtain more evidence of this process, we conducted a 
temperature-variable FT-IR experiment. The progressive 
reduction of the intensity of the carbamate carbonyl band at 
1759 cm
–1
 until it completely disappears, suggests that the 
same mechanism proposed by Holanda et al. operates in the 
first stage of MBZH⋅ClO4 degradation. 
Thermal analysis curves and temperature-dependent 
vibrational spectra are shown in Figure 6 and Inset. This 
experiment shows an improvement in the drug thermal 
stability. In this way, this salt is even more stable than those 
salts and cocrystals previously reported (i.e.: MBZ mesylate 
monohydrate: 50 °C
25
, MBZ nitrate: 150 °C, MBZ 
hydrochloride: 160 °C
44
 and MBZ/valeric acid cocrystal: 186 
°C). This stability could be attributed to the ability of the 
perchlorate anion to form a more stable supramolecular motif 
with the MBZ molecule, preventing the cleavage of the bond 
between the benzimidazole ring and the carbamate moiety at 
lower temperatures. 
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Figure 6. TGA and DTA curves of MBZ perchlorate. Inset: Temperature-
variable FT-IR spectra of MBZ perchlorate. 
 
A second stage of the thermal decomposition starts almost 
immediately (260 °C) and seems to involve two overlapped 
exothermic events with a relative mass loss of 29.00%. Scheme 
S1 shows the propose decomposition mechanism in which the 
cleavage of the amine bond with the removal of ammonia is 
followed by the subsequent elimination of perchloric acid. 
Theoretical mass loss for these consecutives eliminations is 
29.18%, in good agreement with the experimental value. The 
final stage is the complete degradation of the remaining 
compound, 5-benzoylbenzimidazole.  
MBZH⋅SO4CH3 is stable up to 160 °C, when begins a relative 
mass loss of 19.77% (corrected: 17.98%) associated with an 
endothermic signal in the DTA curve (centered at 180 °C) 
consistent with the cleavage of the amine bond and the 
elimination of the entire methylcarbamate moiety (theoretical 
mass loss: 17.94%). Since the end of this event in TGA and DTA 
was not clear, we made use of the first derivate to identify it. 
The removal of methylsulfuric acid and the final degradation of 
the organic product seem to be overlapped and there is no 
defined temperature when these processes begin. Thermal 
analysis curves are shown in Figures S9. The laminar 
disposition of the ions in the crystal structure may be the 
cause of this lesser stability. The presence of the methyl 
groups of methylsulfate anions pointing towards the interior of 
chains “B” and “C” keep layers apart and reduce the ability of 
the anions to interact with the MBZ molecules, preventing a 
better stabilization of the crystal structure and reducing the 
thermal stability of the compound. 
Differences in stability could also be understood in terms of 
the different patterns of intermolecular interactions revealed 
by Hirshfeld surface analysis. In both salts, N–H⋯O H-bonds 
are predominant; however these interactions represent a 
greater percentage of the dnorm surface in MBZH⋅ClO4. Also, an 
important percentage of MBZH⋅SO4CH3 dnorm surface is 
associated with H⋯H contacts. In addition to that, the planar 
stacking arrangement of MBZH
+
 in MBZH⋅ClO4 is stabilized by 
two short contact interactions (with dnorm shorter than the sum 
of the van der Waals radii) and others C⋯C (π⋯C) interactions, 
while in MBZH⋅SO4CH3 the infinite layers are only stabilized by 
discrete short contacts, with dnorm greater than the sum of the 
van der Waals radii. Scheme S1 shows the propose 
decomposition mechanisms for both salts. 
MBZH⋅ClO4 appears to be the most stable solid form of the 
API reported to date, while the stability of MBZH⋅SO4CH3 is 
similar to that of MBZ/butyric acid cocrystal (163.5 °C) 




Solubility and stability in solution and in water suspension 
Using the shake flask saturation method (USP) we 
determine an improvement in a factor of 7 in the apparent 
equilibrium solubility of MBZH⋅ClO4 respect to MBZ A, in 0.1 
mol L
–1
 hydrochloric acid solution. However, this experiment is 
not suitable for the determination of the equilibrium solubility 
of the API. This method is based on the assumption that the 
solid product does not undergo phase transitions or any other 
transformation during the experiment. This apparent solubility 
increase could be considered a drawback since it is similar to 
that of MBZ B which is toxic. Nevertheless, this increment is 
lesser than those previously reported for some MBZ salts and 
cocrystals also obtained by crystal engineering techniques
27
. 
MBZ salts reported here are metastable forms of the drug 
in the conditions of the equilibrium solubility experiment, and 
the transformation to a more stable phase occurs. After 48 
hours in contact with the solvent, samples of MBZH⋅ClO4 salt 
suffered a transformation process.  As shown in Figure S10, 
the comparison of powder X-ray diffraction patterns of those 
samples, before and after the experiment, with those of MBZ 
polymorphs, shows that MBZH⋅ClO4 transforms into MBZ A 
while previous reports indicate that other MBZ salts 
transforms into MBZ C in similar conditions
29,30
. This 
transformation can be justified by the great difference in 
solubility of the two components of the salt: the perchlorate 
anions completely dissolve in the solution, while the MBZ 
molecules precipitate to form the polymorph A. In order to 
determine a more representative value of the solubility of 
these salts, we designed a modified method that takes into 
account the kinetics of the process, both in the solution and in 
the solid phase, which we will apply to study the dissolution 
behaviour of several MBZ salts
30
. 
Once dissolved, MBZ exhibits a behaviour that is 
independent of its solid form. MBZ methanolic solution shows 
three bands in the UV region: 212 nm, 247 nm and 311 nm. In 
ultrapure water (pH 7), these bands are at 209 nm, 249, and 
313 nm. The little effect of the solvent polarity on the position 
of these bands suggests an important hydrophobicity and poor 
solvation in polar media. The spectrum of MBZ shows a 
hypsochromic effect in 0.1 mol L
–1
 hydrochloric acid solution. 
The bands shift to lower wavelength (201, 233, and 287 nm) 
since the absorbent species in this medium is the cation 
MBZH+ (MBZ is completely protonated at pH ≅ 1). The anion 
MBZ(–H)
–
 prevails at pH ≥ 10
35
, and the excess of negative 
charge on the benzimidazole ring shifts the spectrum towards 
higher wavelengths (Figure 7.A). 
Regarding its stability in solution, MBZ is extremely stable 
in methanol and in 0.1 mol L
–1
 hydrochloric acid solutions. The 
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spectra of MBZ solutions fresh and after several days of 
prepared (kept at 25 °C) show little changes in the intensities 
of the bands, attributed to the precipitation of the drug (Figure 
7.B). On the other hand, MBZ undergoes a fast degradation 
process in water solutions when the pH of the medium is 
increased (Figures 7.C and 7.D). This is in good agreement with 



















Figure 7.A. Mebendazole UV-visible spectra in water and methanol.  
B. Stability of mebendazole in methanol and 0.1 mol L–1 hydrochloric 
acid aqueous solution. C. Degradation of MBZ in water pH 7.  
D. Degradation of MBZH⋅ClO4 in water pH 7. 
Conclusions 
Two novel mebendazole (MBZ) bicomponent systems were 
developed and characterized in solid state and in solution. 
Recrystallization of MBZ with perchloric and methylsulfuric 
acids by slow solvent evaporation yielded two ionic solids 
forms of 1:1 stoichiometry: MBZ perchlorate (P21/n) and MBZ 
methylsulfate (P–1). As expected, both anions form a 
supramolecular motif of the R2
2
(8) type through the formation 
of two intermolecular N–H⋯O H-bonds. Ionic pairs are found 
in dimers related by an inversion center assembled in 
antiparallel chains by intermolecular H-bonds, acting the 
anions as bridges between MBZ molecules. Several other 
important H-bonds and short-contact interactions stabilized 
the crystal packings. Hirshfeld surface analysis revealed that 
the predominant intermolecular interactions are the N–H⋯O 
H-bonds where the three N atoms of MBZH
+
 acts as donors. 
MBZ perchlorate is stable up to 210 °C, when occurs the 
endothermic elimination of the methylester moiety of the 
drug. We found an improvement in the thermal stability of the 
drug, since this salt is more stable than MBZ polymorph and 
other multicomponent systems previously reported. On the 
other hand, MBZ methylsulfate first degradation step begins at 
160 °C and follows a different mechanism. These formulations 
avoided polymorph conversion and showed good stability in 
the solid state when they were stored at room temperature. 
Preliminary experiments showed an improvement in MBZ 
perchlorate with respect to MBZ in a factor of 7. However 
further experiments are needed to study the kinetics aspects 
of both the dissolution process of these salts and the stability 
of the drug in aqueous media. 
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